Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Non-Current Liabilities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $12.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Total Non-Current Liabilities rose 48.48% year-over-year to $12.1 million, compared with a TTM value of $12.1 million through Sep 2023, up 48.48%, and an annual FY2022 reading of $9.0 million, up 29.11% over the prior year.
  • Total Non-Current Liabilities was $12.1 million for Q3 2023 at Terns Pharmaceuticals, down from $14.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $23.0 million in Q4 2020 and bottomed at $6.0 million in Q2 2021.
  • Average Total Non-Current Liabilities over 4 years is $10.2 million, with a median of $8.4 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities tumbled 69.71% in 2021, then soared 109.73% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $23.0 million in 2020, then crashed by 69.71% to $7.0 million in 2021, then increased by 29.11% to $9.0 million in 2022, then surged by 34.82% to $12.1 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for TERN at $12.1 million in Q3 2023, $14.5 million in Q2 2023, and $12.5 million in Q1 2023.